Evidence map›Paper›PMID 33427877›Full record

ArticleThe Journal of experimental medicine2021

Stem cell origins of JMML.

Sriram Sundaravel, Ulrich Steidl

Open access · bronzeAbstract readComment
In one paragraph

Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sriram SundaravelAlbert Einstein College of Medicine-Montefiore Medical Center, Bronx, NY.
Ulrich SteidlAlbert Einstein College of Medicine-Montefiore Medical Center, Bronx, NY.
Albert Einstein College of Medicine · US

Funding

Mechanisms of Formation and Progression of Preleukemic Stem CellsR01CA217092 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI STEIDL, ULRICH · 2017 to 2021
$2.0M
Leveraging epigenetic and epitranscriptomic aberrations in cancer to identify molecular targets for designing therapyK00CA223044 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SUNDARAVEL, SRIRAM · 2019 to 2022
$379k
Cancer Research UK 27723Medical Research Council MR/L006340/1Medical Research Council MR/M00919X/1Medical Research Council MR/T014067/1NCI NIH HHS K00 CA223044NCI NIH HHS R01 CA217092
6 · The paper itself

Abstract

In this issue of JEM, Louka et al. (https://doi.org/10.1084/jem.20180853) report that leukemia stem cells lie within the phenotypic hematopoietic stem cell and progenitor cell compartments in juvenile myelomonocytic leukemia (JMML). Furthermore, they identify several candidate biomarker/therapeutic targets, such as CD96 and SLC2A1, that are of translational significance in JMML.

Indexed as

Leukemia, Myelomonocytic, JuvenileHematopoietic Stem CellsHumans

Identifiers

PMID33427877
PMCPMC7802372
OpenAlexW3120512602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.